- CEO
- Guang Qing Li
- Full Time Employees
- 857
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Liaocheng China
- IPO Date
- Sep 11, 2023
- Business
- Shandong Sinoglory Health Food Co., Ltd. is an agricultural processing and biotechnology company primarily engaged in the research, development, production, and sale of soybean deep-processing products and plant-based protein ingredients. Founded in December 2000 and headquartered in Liaocheng, Shandong Province, China, the company operates across the agro-industrial and food ingredient sectors. Its comprehensive product portfolio includes soy protein isolates; soy protein concentrates; textured soy protein and textured vegetable protein granules; soy dietary fiber; edible low-temperature soybean meal and flakes; crude soybean oil; and refined soybean oil. These products serve as essential raw materials and functional additives across multiple end-market applications, including meat processing, emulsified sausages, vegetarian and plant-based meat substitutes, dairy alternatives, nutrition beverages, baked goods, snack foods, sports nutrition, and animal feed.
The company operates large-scale soybean processing facilities integrating procurement, crushing, extraction, and bio-refining under a circular economy model designed for total utilization of non-GMO soybean resources. In addition to serving domestic food manufacturers, distributors, and food service providers across China, Shandong Sinoglory exports its product lines to international markets spanning approximately 100 countries and regions across Europe, North America, Asia-Pacific, the Middle East, Africa, and South America.
In recent corporate developments, the company underwent a major shift in ownership and corporate control in 2026 when Shandong provincial state-owned capital acquired a controlling stake. Shandong Land Development Group Co., Ltd., backed by the State-owned Assets Supervision and Administration Commission of the Shandong Provincial People's Government (Shandong SASAC), became the controlling shareholder through a transaction valued at approximately CNY 893 million, comprising a 22.01 percent equity transfer from the founding shareholder group along with a targeted private placement to inject growth capital. Under state-owned backing, Shandong Sinoglory is expanding its core processing capacity, strengthening upstream non-GMO supply chain synergies, and broadening its research and development pipeline into high-margin health ingredients, including functional lipids, postbiotics, yeast protein, and yeast beta-glucan.